Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PRAN

Alterity Therapeutics (PRAN) Stock Price, News & Analysis

Alterity Therapeutics logo

About Alterity Therapeutics Stock (NASDAQ:PRAN)

Advanced Chart

Key Stats

Today's Range
$3.98
$4.22
50-Day Range
$0.95
$2.06
52-Week Range
$1.09
$2.91
Volume
22,739 shs
Average Volume
130,956 shs
Market Capitalization
$36.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Receive PRAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRAN Stock News Headlines

Alterity Therapeutics to List New Securities on ASX
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Alterity Therapeutics raises A$40M in placement
See More Headlines

PRAN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include Meta Platforms (META), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA) and Conatus Pharmaceuticals (CNAT).

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$150,000.00
Book Value
$1.40 per share

Miscellaneous

Free Float
N/A
Market Cap
$36.31 million
Optionable
Not Optionable
Beta
1.05
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:PRAN) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners